business
Hosted by STAT · business · EN
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
38%
Guest openness
Selective
Sign up to generate a grounded pitch for The Readout Loud.
Signup to Generate a PitchSTAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
The Readout Loud is hosted by STAT. The show has published 423 episodes to date.
Recent episodes include "419: Assessing Merck and Moderna's mRNA cancer vaccine" (30 October 2026, 20 minutes), "418: Remembering STAT’s Helen Branswell" (23 October 2026, 35 minutes), and "417: Hospitals' next lucrative bet, longevity clinics" (16 October 2026, 20 minutes).
The Readout Loud publishes roughly weekly, with episodes averaging 37 minutes across 423 episodes.
Booking probability for The Readout Loud is 38%, and the host is rated Selective on guests. The Readout Loud requires a Pod Score of 80 or higher. The Readout Loud's contact route on record: verified email.
The strongest fits for The Readout Loud are Scientific Research & Development. The Readout Loud has a business audience.
STAT hosts The Readout Loud, a business podcast with 423 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
The Readout Loud
What is Adam doing in Spain? How did doctors react to detailed data on Merck and Moderna's mRNA cancer vaccine? And what are the next big advances in oncology? On this week's episode of “The Readout LOUD,” STAT's...
The Readout Loud
Helen Branswell was a renowned infectious disease reporter who earned the respect and admiration of experts and public health officials with her authoritative, prescient reporting on the flu, polio, Ebola and the...
The Readout Loud
Longevity medicine is now estimated to be a multitrillion dollar industry. But what are people paying for, and does it work? On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on STAT...
The Readout Loud
On this week’s episode of "The Readout LOUD": Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s new trust-in-science reporter Nicholas Florko...
The Readout Loud
"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development means for the biotech industry. The hosts also...
The Readout Loud
International researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the future of American medical research? We...
The Readout Loud
On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did they fail? And what does this mean...
The Readout Loud
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We...
The Readout Loud
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive...
The Readout Loud
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction...
The Readout Loud
Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner? We...
The Readout Loud
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this...
The Readout Loud
This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its opposition to a closely watched gene...
The Readout Loud
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We...
The Readout Loud
Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than...
The Readout Loud
On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” That sounds alarmist...
The Readout Loud
On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conversations and...
The Readout Loud
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his policies will stick, and what we know about...
The Readout Loud
On this week’s episode of "The Readout LOUD," we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat about this week’s notable news, including...
The Readout Loud
Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all that and more on...
Recent guests on The Readout Loud. Study who booked and why before you pitch.
senior infectious diseases reporter, StatNews
Yes & Therapy LLC
healthcare reform advocate, attorney, former director of New Jersey’s public sector health plan, Northwood Presbyterian Church
Business of Health Care Reporter, Little Shamokin Creek Watershed Association
PitchCentric classifies The Readout Loud under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ
